Who will suffer from hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors

The development of immunotherapy has resulted in a paradigm shift for the treatment of advanced non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors (ICIs) [i.e., programmed cell death 1 (PD-1)] and programmed cell death ligand 1 (PD-L1 inhibitors) are particularly important in the treatment of NSCLC, which is associated with poor prognosis. These agents have become a cornerstone of lung cancer treatment.